Ionis Pharmaceuticals Inc (IONS)

[surf1944]

8:01AM ISIS Pharm reports 'positive' Phase 1 data on three drugs in development to treat metabolic disorders (ISIS) 9.00 : Co announces positive results from Phase 1 studies of three drugs, ISIS-PTP1BRx, ISIS-GCGRRx and ISIS-GCCRRx, in development to treat metabolic disorders, including type 2 diabetes. In all three Phase 1 studies, the drugs were safe and well tolerated with early encouraging data that supports the unique mechanism of each drug. All three drugs are part of Isis' metabolic franchise and are designed to act through distinct mechanisms to improve insulin sensitivity and/or reduce glucose production. In the Phase 1 study of ISIS-PTP1BRx in obese healthy volunteers, Isis observed encouraging data in measures of insulin sensitivity and in a biomarker associated with weight loss. Previous clinical experience with the PTP-1B inhibitor ISIS 113715 demonstrated that PTP-1B inhibition improved glucose control and reduced LDL-cholesterol without causing weight gain. Additionally, co's Phase 1 study ISIS-GCGRRx displayed a good safety profile with no clinically significant increases in blood pressure or lipids and with no hypoglycemia